Covid-19

Patient receiving vaccine
#Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Korea #SARS-CoV-2

Adjuvanted Covid-19 vaccine elicits stronger immune response

Researchers from Korea conducted a clinical trial to assess the immunogenicity and safety of GBP510/AS03 relative to the ChAdOx1-S vaccine. The interim results show that GBP510/AS03 had an acceptable safety profile and induced stronger antibody responses when compared with ChAdOx1-S GBP510 is a recombinant… Read More

#News

Hospital patient on ventilator
#Biomarkers #Collaboration #Covid-19 #GeNeuro #Long Covid #Personalised medicine #Verily

Partners take a personalised approach to long Covid

GeNeuro and Verily will work together to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein (W-ENV) in SARS-CoV-2 infection. Through this collaboration, the companies will build on results published earlier this year, which evidenced the in vitro activation of HERV-W by SARS-CoV-2 in… Read More

#Editor's Choice #News

Long Covid
#Antivirals #Burton NHS Foundation Trust #Covid-19 #Gilead Sciences #Long Covid #University Hospitals of Derby #University of Exeter

Could a common antiviral treat long Covid?

A UK-based study will investigate whether a common anti-viral medication could double up as a treatment for long Covid. The project involves teams from the University Hospitals of Derby and Burton NHS Foundation Trust and the University of Exeter, in collaboration with Gilead Sciences. Read More

#News #Trending News

Antibodies attack Covid-19
#Covid-19 #Harvard Medical School #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #University of Oxford

AI tool predicts new viral variants and could improve vaccines

The UK’s University of Oxford is taking the lead on two collaborative international projects to improve the response to new Covid-19 variants and contribute to future pandemic preparedness. Researchers at Harvard Medical School (HMS) in the US and the University of Oxford have developed a new… Read More

#News #Trending News

#Autoimmune disease #Axcella Therapeutics #Chronic Fatigue Syndrome #Covid-19 #Long Covid

Long Covid: A call to action for drug developers

According to the National Institutes for Health, some form of long Covid affects around 10% of people infected with Covid-19, with fatigue being the most common symptom. Despite the size of the market and the global impact, there are currently no effective treatments. Diana Spencer caught up with Bill Hinshaw,… Read More

#Exclusive Content

Vaccine
#Covid-19 #Covid-19 vaccine #FDA #Immunology / Virology & Vaccines #Novavax #Omicron

Novavax Covid-19 vaccine updated for XBB.1.5 variant

Novavax has become the next company to have an updated version of its Covid-19 vaccine approved in the US. The Food and Drug Administration (FDA) amended the emergency use authorisation (EUA) of the Novavax Covid-19 Vaccine, Adjuvanted, for use in individuals 12 years of age and… Read More

#News

Covid-19
#Antivirals #Covid-19 #Covid-19 treatment #Immunology / Virology & Vaccines #Virus mutation

Widely-used antiviral induced SARS-CoV-2 mutations

Researchers have uncovered a link between antiviral drug molnupiravir and a pattern of mutations in the SARS-CoV-2 virus. Molnupiravir induces mutations in the virus’s genome during replication, with the aim of damaging or killing the virus. It was one of the first antivirals available on the… Read More

#Editor's Choice #News

RNA strand
#Covid-19 #RNA #RNA sequencing #Roundtable

Register now to join our roundtable on the delivery of RNA therapeutics

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this… Read More

Webinar date:
Sponsored by Azenta Life Sciences
#News

Patient receiving vaccine
#Covid-19 #EU #Europe #Immunology / Virology & Vaccines #Vaccines

EU’s position as vaccines leader “at risk”, report reveals

The EU has historically been a leader in vaccine research, development and manufacturing, but is now seeing a decline in vaccine research, according to data published by Vaccines Europe (VE). The EU has hosted approximately 20% of global vaccine clinical trials over the past two decades, as well as research… Read More

#News #Trends & Analysis

Covid-19 vaccines
#Covid-19 #Covid-19 vaccine #ICON #Immunology / Virology & Vaccines #Phase II trial

Partners to execute next generation Covid-19 vaccines clinical trial

ICON, a healthcare intelligence and clinical research organisation, with the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, will execute a clinical trial to evaluate the effectiveness of next-generation Covid-19… Read More

#News

RNA
#Covid-19 #RNA #RNA sequencing #Roundtable

Roundtable: Panellists discuss the future RNA pipeline

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this… Read More

Webinar date:
Sponsored by Azenta Life Sciences
#News

Long Covid
#Covid-19 #Immunology #Long Covid #Psychiatry #SARS-CoV-2

New post-Covid study links infection and retrovirus 

A Translational Psychiatry publication indicates that SARS-CoV-2 infection, even when unnoticed or asymptomatic, can have an influence on the activation of the Human Endogenous Retrovirus W (W-ENV) protein in psychotic patients, in a context of innate immune inflammation.   GeNeuro, a biopharmaceutical company developing treatments… Read More

#Covid-19 #News

microRNA
#Covid-19 #RNA #RNA sequencing #Roundtable

Roundtable: Discover how Covid-19 has influenced RNA research

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this… Read More

Webinar date:
Sponsored by Azenta Life Sciences
#News

Close up of vaccine syringe
#BioNTech #Comirnaty #Covid-19 #Covid-19 vaccine #MHRA #Omicron #Pfizer

UK regulator approves Pfizer/BioNTech’s adapted Covid-19 vaccine

Approval has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Pfizer/BioNTech Covid-19 vaccine that targets the Omicron XBB 1.5 subvariant. The new version of Comirnaty was found to meet the UK regulator’s standards of safety, quality and effectiveness and has… Read More

#News #Trending News

RNA
#Covid-19 #RNA #RNA sequencing #Roundtable

What are the challenges in the delivery of RNA therapeutics?

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this… Read More

Webinar date:
Sponsored by Azenta Life Sciences
#News

Long Covid
#Axcella Therapeutics #Covid-19 #Long Covid #US patent

Axcella granted US patent for long Covid fatigue treatment

The US Patent and Trademark Office (USPTO) has granted a patent for Axcella Therapeutics’ long Covid treatment candidate AXA1125. AXA1125 is a novel composition of endogenous metabolic modulators (EMMs) designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with fatigue. In April, The… Read More

#News